Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York